Viyash Scientific Ltd

- The company has completed most of its significant capex investments in the last few years, establishing a base to support business growth for the next several years. - For the current financial year (FY ’25), capex is expected to be subdued and in the range of INR 50 crores to INR 60 crores, primarily to support global formulation opportunities. - Strategic investments focus on inorganic growth through disciplined M&A primarily in companion animal formulations and bolt-on brands or licensing partnerships. - On the API side, the company looks for acquisitions that can strengthen or shorten R&D time-to-market, improve scale, or internalize operations for profitability. - There are no large-scale acquisitions planned immediately due to current leverage, but the company is open to smaller bolt-on deals and partnerships. - Financing options are available through committed investors and alternate structures, so finance is not seen as a barrier for strategic opportunities.

- The company targets early double-digit top-line growth over the next 2 to 3 years, aiming for 10% to 12% revenue growth annually. - Growth drivers include approximately one-third volume growth, one-third price increases, and one-third from new products and launches. - Formulation business volumes are expected to grow around 5% to 7% across most markets. - The Turkey business is expected to grow in volume while maintaining pricing discipline, with exports from Turkey increasing, especially to Middle East and North Africa. - The India formulation business is poised for growth with recent team expansions and new product launches expected to accelerate revenue in the next 12 to 18 months. - The European market showed strong 34% YoY growth, supported by new business opportunities and portfolio restructuring. - The vaccine business is seen as a new growth avenue, with plans to add more products over the next 12 to 24 months. - Overall, the company expects to sustain growth momentum while optimizing working capital and operational efficiencies.

- SeQuent Scientific targets early double-digit top-line growth over the next 2-3 years. - EBITDA margins are expected to reach mid-teens by the end of FY '25 and progress to high teens subsequently. - The company aims for consistent, profitable, and sustainable growth driven by operational excellence and portfolio expansion. - Margin improvements are supported by operational efficiencies, pricing actions, and portfolio rationalization. - The company foresees margin and profit growth from geographic expansions, especially in Europe and Turkey. - Debt levels are expected to reduce substantially over 3 years, lowering interest costs and supporting earnings improvement. - India formulations and companion animal businesses are key growth areas targeted to rise from less than 5% to ~15% over 3-5 years. - Inorganic growth (M&A/licensing) could accelerate earnings depending on execution and market conditions.

The transcript does not provide specific details on the current or expected order book or pending orders for SeQuent Scientific Limited. However, relevant insights related to business outlook and growth include: - The company is experiencing strong growth, particularly in Europe and emerging markets like Turkey. - There is increased demand due to disease outbreaks and new product introductions. - The company is expanding its formulations business in India, expecting accelerated growth in 12 to 18 months. - Exports from Turkey are increasing, supporting foreign exchange and operational efficiencies. - Focus on organic growth supported by potential bolt-on acquisitions and partnerships. - Management emphasizes agile response to market conditions, with stable expected volume growth of 5-7% in existing portfolios. No explicit numeric data or order book size figures are mentioned in the provided pages.

- The company is currently not planning large-scale acquisitions funded directly from its balance sheet due to leverage concerns. - For smaller bolt-on acquisitions or partnerships, the company is open and able to finance these without strain. - There is a committed principal promoter and investor support, so financing larger transactions through different structures (not necessarily on the balance sheet) is possible. - No explicit current or future plans were shared regarding raising new equity. - Debt restructuring has simplified borrowing and created additional lines for future support, implying readiness for funding if required. - Overall, finance availability is not expected to be a challenge for strategic opportunities, but no formal new fundraising (debt or equity) announcements were made.